Market Research Report
Global Cardiac Rhythm Management Devices Market - 2019-2026
|Published by||DataM Intelligence||Product code||803256|
|Published||Content info||130-180 Pages
Delivery time: 1-2 business days
|Global Cardiac Rhythm Management Devices Market - 2019-2026|
|Published: July 1, 2019||Content info: 130-180 Pages||
Cardiac rhythm management (CRM) devices are used to treat patients with abnormal heart rhythm disorders. Heart rhythm problems can be classified into abnormally slow (bradycardia) and abnormally fast (tachycardia). These conditions are managed by cardiac rhythm management devices such as defibrillators (ICD), pacemakers, and cardiac resynchronization therapy (CRT).
Increased hypertension and excessive smoking lead to high risk of cardiac disorders. This may result in more need for cardiovascular therapeutic instruments such as CRT devices, Pacemakers, and ICDs are considered as standard treatment options for cardiac rhythm management across the world.
The global cardiac rhythm management devices market was worth $ XX billion in 2018 and is forecasted to reach $ XX billion by 2026, at a CAGR of XX% during the forecast period.
The increasing cases of cardiac disorder are one of the factors fueling the global cardiac rhythm management market.
For instance, According to National Health Service, Arrhythmias or heart rhythm problems are experienced to increase by more than 2 million people each year in the UK. In the UK each year 30,000 patients suffer from an atrial fibrillation related stroke.
According to Center of Disease Control and Prevention (CDC), approximately 2% of people younger than age 65 have AFib, while about 9% of people aged 65 years or older have AFib in U.S. around 2.7 to 6.1 million people in the United States have AFib. With the aging of the U.S. population, this number is expected to increase.
The risk for AFib increases with age. High blood pressure, which also increases in risk with advancing age, accounts for 14% to 22% of AFib cases. More than 750,000 hospitalizations occur each year because of AFib. The condition contributes to an estimated 130,000 deaths each year.
Based on product the global market for Cardiac rhythm management devices is broadly segmented as by pacemakers, defibrillators, and cardiac resynchronization therapy (CRT).
Currently defibrillators is the dominant segment and it accounts for approximately XX% of the market, due to the launch of new products and regulatory approval for defibrillators.
For instance, In September 2017, Boston Scientific have introduced implantable cardioverter defibrillator (ICD) and cardiac resynchronisation therapy defibrillator (CRT-D) systems featuring the HeartLogic Heart Failure Diagnostic to help improve heart failure (HF) management.
In July 2017, Physio-Control Inc., have received US FDA Premarket Approval (PMA) for HeartSine samaritan PAD 360P (SAM 360P) to sale in the United States. HeartSine samaritan PAD 360P is to analyze cardiac rhythm and automatically deliver electric shock to victims of sudden cardiac arrest without the use of a shock button. Its user-friendly visual and audio prompts, such as CPR coaching, verbally guide the rescuer through the CPR process.
In August 2016, Boston Scientific have received U.S. Food and Drug Administration (FDA) approval for the EMBLEM MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic resonance (MR) conditional labeling for all previously implanted EMBLEM S-ICD Systems.
In March 2015, Boston Scientific Corporation, have received FDA and CE Mark approval of the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) System. The EMBLEM S-ICD System is a treatment option that provides protection for patients at risk of sudden cardiac arrest (SCA).
The global cardiac rhythm management devices market is segmented into North America, Europe, Asia Pacific, South America and ROW.
North America is dominating the global cardiac rhythm management devices market, due to the increase in regulatory approval and product launches for cardiac rhythm management devices.
For instance, in January 2018, ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, have received premarket approval (PMA) by the U.S. Food and Drug Administration (FDA) to market and distribute its full line of defibrillators in the U.S.
In April 2017, Physio-Control have received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) to sell its HeartSine samaritan PAD 360P (SAM 360P) fully automatic external defibrillator (AED) in the U.S.
In February 2017, Abbott, have received U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for both the Assurity MRI pacemaker and the Tendril MRI pacing lead. The device have the ability to undergo full body magnetic resonance imaging (MRI) scans. Assurity MRI pacemaker is the world's smallest, longest-lasting wireless MRI-compatible pacemaker.
In November 2016, Medtronic plc have received U.S. Food and Drug Administration (FDA) approval for the Claria MRI Quad Cardiac Resynchronization Therapy Defibrillator (CRT-D) SureScan device for patients with heart failure.
The product launch and regulatory approval for cardiac rhythm management devices is one of the key factor driving the global cardiac rhythm management devices market.
For instance, in June 2018, Royal Philips, a global leader in health technology, have introduced Philips HeartStart Onsite automated external defibrillators (AEDs) to create a cardiac arrest response system in collaboration with Starting Hearts and medic assist.
In March 2017, Zoll Medical Corporation have received FDA premarket approval for its wearable external defibrillator for use in the hospital. Zoll got approval for its LifeVest, and the company have developed similar product for home use.
In May 2017, Medtronic plc, have received U.S. Food and Drug Administration (FDA) approval for a portfolio of quadripolar cardiac resynchronization therapy-pacemakers (CRT-Ps) that improve therapy delivery for patients with heart failure.
In April 2016, St. Jude Medical, Inc., a global medical device company, have received U.S. Food and Drug Administration (FDA) approval for MultiPoint Pacing technology and launch first U.S. implants of the Quadra Assura MP cardiac resynchronization therapy defibrillator (CRT-D). MultiPoint Pacing technology is a revolutionary approach designed for CRT patients who are not responsive to other pacing options.